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47Leukemias are one of most common malignancies worldwide. There is a substantial need for new chemo-
therapeutic drugs effective against this cancer. Doxorubicin (DOX), used for treatment of leukemias and
solid tumors, is poorly efficacious when it is administered systemically at conventional doses. Therefore,
several strategies have been developed to reduce the side effects of this anthracycline treatment. In this
study we compared the effect of DOX and doxorubicin–transferrin conjugate (DOX–TRF) on human leu-
kemia cell lines: chronic erythromyeloblastoid leukemia (K562), sensitive and resistant (K562/DOX) to
doxorubicin, and acute lymphoblastic leukemia (CCRF-CEM). Experiments were also carried out on nor-
mal cells, peripheral blood mononuclear cells (PBMC). We analyzed the chemical structure of DOX–TRF
conjugate by using mass spectroscopy. The in vitro growth-inhibition assay XTT, indicated that DOX–TRF
is more cytotoxic for leukemia cells sensitive and resistant to doxorubicin and significantly less sensitive
to normal cells compared to DOX alone. During the assessment of intracellular DOX–TRF accumulation it
was confirmed that the tested malignant cells were able to retain the examined conjugate for longer peri-
ods of time than normal lymphocytes. Comparison of kinetic parameters showed that the rate of DOX–
TRF efflux was also slower in the tested cells than free DOX. The results presented here should contribute
to the understanding of the differences in antitumor activities of the DOX–TRF conjugate and free drug.
 2013 Published by Elsevier Ltd.48
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69Doxorubicin (DOX) is an effective antineoplastic agent with
antitumor activity against many solid tumors and leukemias but
its utilization in anticancer therapy is limited by a number of fac-
tors including their low therapeutic index and the rapid emergence
of drug resistant cell populations (Jungsuwadee et al., 2012;
Swiech et al., 2012). The clinical use of DOX is limited, due to
cumulative, dose-dependent side effects such as cardiotoxicity








78cin and other anthracyclines (Luo et al., 2011; Salvatorelli et al.,
2012). The goal of anticancer drug development is to identify
agents that are effective cancer medicines and yet have minimal
systemic side effects. A way to improve the selectivity of cancer
therapy is to direct drug activity against therapeutic targets that
display altered levels of expression in malignant versus normal
cells (Kratz et al., 2008). The use of drug carriers, such as liposomes,
dendrimers, nanoparticles, antibodies and others may be part of
this approach in allowing increased intracellular concentrations
of the cytotoxic agents in cancer cells, therefore helping to over-
come the chemoresistance of neoplastic cells (Haag and Kratz,
2006).
Effective and selective anticancer drug carriers are protein con-
jugates of anthracyclines. Transferrin (TRF) is a plasma protein that
can be used as a carrier of anthracyclines because receptors for this
protein are overexpressed at the surface of cancer cells, due to the
high demand of tumor cells for iron ions, which participate in
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25 September 2013et al., 2006). Moreover, this protein is commercially available and
does not produce an immune response in patients. In addition,
intensive transport of transferrin to tumor cells is possible due to
the increased permeability of blood tumor vessels. The diameter
of the slots in the tumor capillaries range from 100 to 1200 nm,
while in normal tissues it is about 100 times smaller (Nevozhay
et al., 2007).
Transferrin has recently shown promise as a carrier for antican-
cer agents. A mitomycin–transferrin conjugate, forming cytostatic
cross-links with DNA, showed a cytotoxic effect on HepG2 cells
(Human hepatocellular liver carcinoma) and HL60 cells (Human
promyelocytic leukemia), with inhibition of cell proliferation
in vitro (Tanaka et al., 2001).
The purpose of our work is to analyze the effectiveness of the
transport of a DOX–TRF conjugate through the cellular membrane
of human leukemia cells and its intracellular distribution in com-
parison with free doxorubicin. It has been estimated that leukemia
cells have from 150,000 to 1,000,000 TRF receptors on their
surface, while normal cells are deficient in this type of receptor
(Lubgan et al., 2009; Barabas et al., 1992). We have chosen two hu-
man leukemia cell lines: chronic erythromyeloblastoid leukemia
cells (K562) and acute lymphoblastic leukemia cells (CCRF-CEM),
which present substantial differences in oncogenesis mechanisms
and drug sensitivity. Peripheral blood lymphocytes were used as



















1802. Materials and methods
2.1. Chemical compounds
DOX was obtained from Sequoia Research Products (Pang-
bourne, United Kingdom). RPMI 1640 bicarbonate medium was
supplied by Lonza (Vievres, Belgium), fetal bovine serum (FBS),
penicillin and streptomycin were from Gibco (Edinburgh, Scot-
land). Human transferrin, glutaraldehyde and ethanolamine used
for conjugation were purchased from Sigma. All other chemicals
and solvents with high analytical grade were obtained from POCH
S.A. (Gliwice, Poland).
Doxorubicin was coupled to TRF using the modified conjugation
procedure developed by Berczi et al. (1993), Patent claim No WIPO
ST 10/C PL 402896). DOX–TRF was chromatographed on a column
of Sepharose CL-4B. The optical spectrum of each fraction was
determined using a UV/VIS spectrophotometer (Perkin Elmer
SL-5B) and the collected fractions were analyzed by sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE),















1962.2. Mass spectrometry experiments – MALDI-TOF measurement
The molecular weight of doxorubicin–transferrin conjugate was
determined by mass spectrometry (MS). We calculated the mass-
to-charge ratio of transferrin or its conjugate with doxorubicin,
and the mass spectra of tested compounds were evaluated. Mass
difference allowed the determination of themolar ratio of drug con-
jugated to protein. Identification of the molecular weight wasmade
usingMALDI-TOF spectrometer (Bruker Co.) in a linear ionmode for
positive ions detection. For this purpose, solutions of native protein
(transferrin) and transferrin conjugated to doxorubicin (DOX–TRF)
were prepared at a concentration 15 lg/ml. A saturated solution of
matrix–sinapic acid (SA) in 50% acetonitrile and 0.05% trifluoroace-
tic acid was prepared. The native protein or the conjugate was
mixed with the matrix solution in a volume ratio of 1:1, and
0.5 ll of the sample was applied to a steel plate.Please cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.org2.3. Mass spectrometry experiments – Ion Mobility Mass Spectrometry
(IMS)
In order to verify that the shape and size of transferrin did not
change after attachment of doxorubicin, we compared the colli-
sional cross section (X (Å2)) of native transferrin and DOX–TRF con-
jugate. For this experiment we used a hybrid mass spectrometry
technique combined with the separation of ions according to their
collisional cross section (IMS, Ion Mobility Mass Spectrometry).
Ions generated in the electrospray source enter the ion mobility
device and travel toward the detector with associated drift times
(tD (ms)). The collisional cross section (X) value and tD are linked




where tD is the measured drift time (ms), X is the collisional cross
section (Å2), q is the molecular charge and a, b are the constants that
remain unchanged and determined in a given experiment.
To determine the parameters of the equation it was necessary
to measure protein standards, draw a calibration curve and mea-
sure studied samples under the same condition.
The experiment began with measurements of the drift times
(tD) of standard proteins with known values of m/z and the corre-
sponding collisional cross sections. Cytochrome c and ubiquitin
were measured to draw the calibration curve (Ruotolo et al.,
2008, 2007). Under the same conditions we measured the drift
times for transferrin and the DOX–TRF conjugate.
The measurement was made using an ESI–TOF mass spectrom-
eter (SYNAPT G2 HDMSWaters Co.) in positive ion mode. The spec-
trometer settings were: capillary voltage – 2.5 kV, sampling cone
voltage – 70 V. Solutions of native transferrin and DOX–TRF conju-
gate were prepared at a concentration of 15 lg/ml. They were then
subjected to dialysis against 5 mM ammonium acetate pH 7.4. All
data acquisition and processing were carried out with MassLynx
(V4.1) and DriftScope (V2.1) software supplied with the instru-
ment.2.4. Cell cultures
CCRF-CEM cells were received from Prof. G. Bartosz (Depart-
ment of Molecular Biophysics, University of Lodz, Poland). K562
cells sensitive and resistant to doxorubicin were a kind gift from
Prof. J. Robert at Institute Bergonie, Bordeaux, France. K562/DOX
cells were cultured in continuous presence of 0.02 lM DOX and
the cells were resistant to DOX due to overexpression of the
MDR1 protein (Tsuruo et al., 1986). Peripheral blood mononuclear
cells were obtained from young (23–25 years), non-smoking men.
The lymphocytes were isolated by centrifugation in a density gra-
dient of Histopaque (30 min, 300g, 22 C). Cell viability, evaluated
by trypan blue exclusion, was found to be about 99%. In the case
of lymphocytes, each experiment was performed on cells obtained
from the blood of three different donors. All cells were grown at
37 C in a 5% CO2 atmosphere in RPMI 1640 supplemented with
10% heat-inactivated FBS, penicillin (10 U/ml) and streptomycin
(50 lg/ml).2.5. Cell cytotoxicity assay
The cytotoxicity of DOX and DOX–TRF to human tumor and
normal cells was measured in 96-well plates by a XTT (2,3-Bis
(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxani-
lide inner salt) colorimetric assay. This method is based on the
cleavage of XTT by metabolically active cells. For this purpose,









































































M. Szwed et al. / Toxicology in Vitro xxx (2013) xxx–xxx 3
TIV 3179 No. of Pages 11, Model 5G
25 September 2013in each well in 0.1 ml of culture medium. Then, 0.05 ml DOX or
DOX–TRF of different concentrations were added to the appropri-
ate wells, and cells were incubated with drugs for 72 h. At the
end of incubation, the cells were centrifuged (230g for 10 min at
4 C), and the medium was gently removed. At that time, 50 ll
XTT at the final concentration of 0.3 mg/ml medium was added
to each well and the microplates were incubated for 4 h. The plates
were mechanically agitated for 1 min, and an absorbance at
450 nm was measured with a microplate reader (Awareness Tech-
nology Inc., USA). Cytotoxicity of DOX and conjugate was ex-
pressed as IC50, i.e. the concentration of drug that reduces cell














2852.6. Intracellular accumulation of DOX and DOX–TRF
Intracellular DOX or DOX–TRF accumulation was evaluated by
flow cytometry (LSRII, BD Biosciences). The cells (4  105 in 3 ml
of culture medium) were plated onto 30-mm Petri dishes and incu-
bated at a concentration of 0.5 lM DOX or DOX–TRF for various
periods: 0.5, 1; 2; 4; 6; 12 and 24 h (37 C, 5% CO2). After
incubation, the cells were centrifuged and suspended in ice-cold
PBS. The intensity of drug fluorescence was measured on a Bec-
ton–Dickinson flow cytometer using Flow Jo cytology software;
105 cells were counted in each sample and each experiment was
repeated at least 4 times. As a control, the autofluorescence of
the untreated cells was used. In addition, cells were viewed using
inverted fluorescence microscopy (Olympus IX70, Japan) with a






























3162.7. Estimation of doxorubicin or doxorubicin–transferrin uptake
The amount of DOX and DOX–TRF conjugate taken up by the
cells was determined using flow cytometry (LSRII, BD Biosciences).
Drugs at a final concentration of 5 lM were added to 106cells in
1 ml of medium for periods ranging from 5 to 60 min (37 C).
DOX fluorescence was obtained using 488 nm laser excitation
wavelength. Fluorescence was transmitted through FL2 channel.
The parameter analyzed was the slope of the straight line, consid-
ered as the rate of drug accumulation in cells. The results are pre-
sented as a percent of control (autofluorescence of the untreated
cells taken as a 100%).
2.8. Drug transport and intracellular distribution
The study of the dynamics of DOX and DOX–TRF transport
through the cell membrane was carried out according to the
method described by Przybylska et al. (2001). Cells were seeded
into 96-well plates at a density of 8  104 cells per well in 0.2 ml
of culture medium. The plates were then centrifuged (230g for
10 min at 4 C) and 0.05 ml DOX or DOX–TRF at a concentration
of 2 lM was added. The cells were incubated with drugs for
5–60 min (37 C, 5% CO2). An equal volume of HBSS (140 mM NaCl,
5 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 1 mM Na2HPO4, 10 mM
HEPES, and 1% glucose) was added to the control samples. The
samples containing drug without cells were used as references
for initial drug concentration. At the indicated time points, the
supernatant was moved to black 96-well microtiter plates. The
amount of DOX and DOX–TRF in the medium was evaluated using
fluorescent multiwell plate reader Fluoroskan Ascent FL., Labsystem
Inc (kex = 488 nm, kem = 566 nm). The amount of drug in extracellu-
lar medium and associated with the cells was calculated from the
standard curve, representing the relationship between drug
concentration and fluorescence intensity.
Kinetic parameters associated with DOX and DOX–TRF
transport into lymphocytes and leukemia cells were calculated asPlease cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.orgpreviously described (Andreoni et al., 1996). A simple model of
transport kinetics was assumed. The intracellular concentration
of drug (C) in steady state was taken from the equation:
C ¼ Mtot Mt ð1Þ
where Mtot is the total amount of drug to which cells were initially
exposed and Mt is the amount of drugs in external medium at var-
ious times of incubation.
Furthermore, the initial rate of DOX and DOX–TRF uptake (It=0)
is given as the first derivative of the curve representing
time-dependence of drug transport. At the equilibration state, the
uptake rate constants of drug transport were calculated according
to the assumption that both DOX and conjugate influx followed a
first order equation.
It¼0 ¼ kinMtot ð2Þ
where kin is the influx rate constant. Values of Mtot and kin allowed
the estimation of the quantity of drug taken up by cells (U), which
was then evaluated from the rate equation transformation:
U ¼ Mtotð1 ektin Þ ð3Þ
Under these conditions, the kinetic parameters for drugs effluxed by
cells (kout and Et = 0) were analyzed in the same way from the
curves representing the time dependence of the values gained by
the judgment of the intracellular amount of drug (C) from the
amount of drug taken up by cells (U) at the same incubation time.
2.9. Statistical analysis
Data are expressed as a means ± S.D. An analysis of variance
(ANOVA) with a Tukey post hoc test was used for multiple compar-
isons. Three-way analysis of variance was used to test DOX and
DOX–TRF cytotoxicity, accumulation and uptake between cell
lines. All statistics were calculated using the STATISTICA program
(StatSoft, Tulsa, OK, USA). A P value of <0.05 was considered
significant.
3. Results
3.1. Determination of the molecular weight of the doxorubicin–
transferrin conjugate by mass spectrometry
The analysis of the mass spectrum of native transferrin and
DOX–TRF conjugate (Fig. 1) allows us to determine the molecular
weight of transferrin on 78.40 kDa and DOX–TRF conjugate on
79.50 kDa. Taking into account the fact that free doxorubicin has
a molecular weight 543 Da, we concluded that the conjugate
results from the association of two molecules of DOX and one
molecule of TRF.
3.2. Ion mobility analysis of doxorubicin–transferrin conjugate
Collisional cross section is a physical quantity, which allows the
comparison of the overall shape and size of the transferrin
molecule before and after association to doxorubicin. Fig. 2 shows
a typical spectrum for IMS measurement and shows the depen-
dence of drift time (tD) and m/z value. Each spot on the spectrum
represents a different charge state (z) which is expected for elec-
trospray ionization. For both transferrin and conjugate there were
only single values of drift times for each charge states. This profile
shows that transferrin and the conjugate occur in a homogeneous
structure state. Using the calibration curve, we calculated the
values of collisional cross sections (X (Å2)) for every charge states
of transferrin and the conjugate (Table 1). Charge attachment dur-






















































Fig. 1. Mass spectrum of free doxorubicin and doxorubicin transferrin conjugate.
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does not differ between transferrin and the conjugate.
Results were also compared with the theoretical value of the
collisional cross section of transferrin. Theoretical calculations
were performed using CCS calc (Bruker Co.) software, based on
available data for transferrin in the PDB (Protein Data Bank) data-
base. The calculated value of collisional cross section for transferrin
was 4744 Å2. This shows that theoretical and experimental values
of X are in firm agreement.
Summarizing this experiment, the results indicate that there
was no difference in collisional cross sections between free trans-
ferrin and the DOX–TRF conjugate. This indicates that the conjuga-












As shown in Table 2, the cells presented a significantly different
sensitivity to doxorubicin and DOX–TRF. The three leukemia cell
lines were consistently more sensitive to DOX–TRF than to DOX,
whereas normal lymphocytes were, significantly, 2-fold less
sensitive to DOX–TRF conjugate than to DOX. The conjugate
appears more cytotoxic than the free drug against tumor cells
and less toxic than the free drug against normal lymphocytes. In
addition, DOX–TRF is much less cytotoxic against normal
lymphocytes than against each of the leukemia cell lines, even












3923.4. DOX and DOX–TRF conjugate accumulation in normal and
leukemia cells
To analyze whether the cytotoxic activity of DOX and DOX–TRF
was related to their intracellular level, drug accumulation was esti-
mated as a function of time (Fig. 3). Fluorescence intensity of DOX
in K562, K562/DOX and CCRF-CEM cells reached a maximal level
after 2 h and 4 h incubation, respectively, and drug fluorescence
slowly decreased thereafter (6–24 h). By contrast, DOX–TRF fluo-
rescence progressively increased in leukemia cell lines up to 24 h
incubation. Accumulation of free DOX and DOX–TRF was higher
in CCRF-CEM cells than in K562 cells (about 2 and 2.5-fold respec-
tively); in K562/DOX cells, free drug had amarkedly lower accumu-
lation than in the parental cells, whereas DOX–TRF was similarlyPlease cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.orgaccumulated in both cell lines. In PBMC, DOX fluorescence was as
high as in CCRF-CEM cells, whereas DOX–TRF fluorescence rapidly
reached a maximum level after 1 h incubation and then gradually
decreased. These findings show that there was no obvious relation-
ship between drug accumulation and cytotoxicity since DOX–TRF
was more cytotoxic to and less accumulated within leukemia cells
than DOX. In addition, Pgp-related drug resistance was associated
with a marked reduction in DOX accumulation but not in DOX–
TRF accumulation. Finally, a different mode of accumulation of
DOX–TRF and DOX operates in normal and leukemic cells.
The intracellular location of the compounds in leukemia and
normal cells was evaluated by fluorescence microscopy (Fig. 4).
Alterations in the structure, size and shape of the cell nucleus were
detected after 12 h of treatment with both drugs. DOX–TRF was
mainly located in cytoplasm. At early times of incubation, we
observed a bright red fluorescence in the region of cellular
membrane. In addition, free DOX was mainly accumulated in the
nucleus whereas its conjugate could be gathered in other cell
organelles. In PBMC, DOX and DOX–TRF, fluorescence was
markedly weaker than in leukemia cells, sensitive or resistant to
doxorubicin.3.5. Flow cytometry analysis of the drugs
When studied as a function of time at the concentration of
5 lM, the accumulation of DOX and DOX–TRF conjugate in leuke-
mia cells did not reach a plateau (Fig. 5). In contrast, a plateau was
reached after short incubation times in PBMC. Additionally, the
rate of influx of DOX–TRF was slower than that of DOX in leukemia
cells or PBMC (Fig. 5) (11.7 units for K562, and 35.7 units for CCRF-
CEM). Besides this, the difference between the rate of DOX or DOX–
TRF accumulation was also observed in normal cells during the
time of experiment, since the slope of the rate of accumulation
equalled 7.7 units for DOX and 4.4 units for DOX–TRF, respectively.
The results clearly show that DOX–TRF needs more time to reach
the same level as DOX in leukemic cells.3.6. Transport kinetics and cellular distribution
The transport of DOX and DOX–TRF through the cellular mem-
brane was estimated indirectly from the measurement of the drug














Fig. 2. The conjugate and free transferrin IMS spectrum. The upper panel shows signal series resolved in the domain of m/z (vertical axis) and drift time (tD [ms]) shown on
horizontal axis. Black ellipses mark signals of different charge states, as described. The lower profile panel shows a cross-section for Z = 21 charge state in the domain of drift
time (tD [ms]). The profiles are the same which concludes that collisional cross section of transferrin does not change after attachment of doxorubicin.
Table 1
Collisional cross sections (X [Å2]) for every charge state (z) of transferrin and DOX–
TRF conjugate.
Sample m/z X (Å2) z tD (ms) X/z
Transferrin 4363 4724 18 5,29 262
4134 4812 19 4,92 253
3927 4880 20 4,56 244
3740 5222 21 4,74 249
3570 5368 22 4,56 244
DOX–TRF conjugate 4419 4724 18 5,29 262
4186 4812 19 4,92 253
3977 4880 20 4,56 244
3788 5222 21 4,74 249
3616 5368 22 4,56 244
Table 2
Cytotoxicity of free doxorubicin and doxorubicin conjugated to transferrin in PBMC.
CCRF-CEM and K562 cell lines sensitive and resistant to DOX. The values are the IC50
mean values ± SD of 4–5 independent experiments.
Cell lines IC50 values
DOX (nM) DOX–TRF (nM)
CCRF-CEM 131.21 ± 14.59# 57.16 ± 2.81*,#
K562 269.61 ± 20.13# 72.4 ± 5.67*,#
K562/DOX 2572.35 ± 124.78# 260.97 ± 16.34*,#
PBMC 566.08 ± 54.66 1132.16 ± 109.25*
* Significant differences between cells treated with DOX and DOX–TRF (p < 0.05).
# Significant differences between leukemia cells and PBMC (p < 0.05).
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malignant cells. The curves representing the amount of drug taken
up as a function of time (U) and excluded by cells during the same
time (E) are presented in Fig. 6 and the kinetic parameters evalu-
ated from them are presented in Table 3. We have shown thatPlease cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.orgDOX was transported faster to cells than its conjugate in PBMC,
CCRF-CEM and K562 sensitive cells, whereas DOX–TRF was trans-
ported faster than DOX in K562 resistant cells. In contrast, the rate
of DOX–TRF efflux was lower than that of DOX in leukemia cells
but they were similar for PBMC. The amount of DOX removed by
cells during 60-min incubations was markedly lower in normal
cells than in malignant cells.ytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin
/10.1016/j.tiv.2013.09.013
Fig. 3. DOX and DOX–TRF accumulation in PBMC, CCRF-CEM, K562 and K562/DOX cell lines. Cells were treated with 0,5 lM of both drugs for 0.5 h to 24 h. Results represent
means ± SD of six independent experiments. Significant differences between treated and control cells, taken as 100%: p < 0.05, p < 0.01; significant differences between cells
treated with free doxorubicin and DOX–TRF conjugate: #p < 0.05.
Fig. 4. Intracellular accumulation and distribution of DOX and DOX–TRF in PBMC, CCRF-CEM, K562 and K562/DOX cell lines. The cells were incubated with 0.5 lMDOX alone
and conjugated to TRF for 0.5 and 12 h. The cells were monitored using an Olympus IX70, Japan; magnification 400.
6 M. Szwed et al. / Toxicology in Vitro xxx (2013) xxx–xxx
TIV 3179 No. of Pages 11, Model 5G
25 September 2013
Please cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin




























































Fig. 5. Uptake of DOX or DOX–TRF by PBMC, CCRF-CEM, K562, K562/DOX cells in the function of time. Moreover, flow cytometry analysis allowed the evaluation of the values
of direction components, which are the measurement of the drug influx to the cell. The results are the means ± SD of 3–4 independent experiments. In each line as in PBMC
we observed a significant difference between transport of free DOX and DOX–TRF.
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Tumor-targeted delivery of anticancer drugs appears to be one
of the most important ways to improve cancer chemotherapy
(Liu et al., 2010; Maeda et al., 2009). Macromolecular drug carriers
have been shown to be effective in overcoming many obstacles of
conventional chemotherapy. A macromolecular drug carrier can
easily enter the tumors and enhance drug accumulation due to
vascular leakiness and important lymphatic drainage in cancers
(Moon et al., 2007). The studies carried out on rat models have
shown that human recombinant melanotransferrin (p97), cova-
lently linked with paclitaxel (PTX) and DOX, could be actively
transported across the Blood–Brain–Barrier (BBB) and its accumu-
lation in an in vitro model was 10–15 times higher than the com-
bination of free drugs (Karkan et al., 2008).
The knowledge about the structure of proteins which can be
used as drug carriers for rational drug design is still very limited.
This is due to the poor suitability of classical methods of structural
analysis for the investigation of homogenous peptides or proteins.
MS is currently the most accurate analytical method with a wide
variety of applications for the analysis of physicochemical proper-
ties of potential drug carriers (Kloniecki et al., 2011). It allows the
evaluation of three parameters characterizing given ion beams: the
ion mass and the individual ion’s contents and energy. We assessed
by this method that one molecule of protein can bind two mole-
cules of drug.
These results allowed us to carry out ion mobility separation
measurements, also used to characterize Ab peptides in
Alzheimer’s disease (Cappai and Barnham, 2008; Kokubo et al.,
2005). IMS provided a simple and fast insight into the shape ofPlease cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.orgDOX–TRF conjugate allowing the testing of changes in the struc-
ture of transferrin after drug binding. Drift times measurements
led to the conclusion that the structure of TRF after doxorubicin
binding did not change, because there was no difference between
the collisional cross sections for TRF and DOX–TRF.
The conjugation of DOX to TRF greatly enhanced DOX cytotox-
icity in leukemic cells. This was the reverse in PBMC, which were
more resistant to the conjugate than to DOX alone. Chlorambu-
cil-TRF conjugates were also shown to be effective in cancer ther-
apy. This formulation was active against the breast cancer cell line
MCF-7 and the leukemia cell line MOLT4 with a decrease in chlor-
ambucil IC50 parameter of about 18-fold. Studies in mice have con-
firmed that this formulation of chlorambucil is much better
incorporated by tumor cells than free drug (Beyer et al., 1998).
Similarly, a cisplatin–transferrin conjugate presented a much high-
er cytotoxicity than the free drug. Inuma et al. (2002) reported that
it increased significantly the lifespan of mice bearing the MKN45P
gastric cancer.
In addition, DOX–TRF conjugates may overrun the multidrug
resistance barrier which limits the success of cancer therapies.
Lubgan et al. (2009) showed that DOX–TRF is about 300 times
more cytotoxic than doxorubicin to the doxorubicin-resistant
HL60 cell line. DOX-antibody conjugates may also be worthy of
interest. Starting from the fact that the midkine receptor is a
growth factor receptor preferentially expressed in tumor cells, Inoh
et al. (2006) studied an anti-midkine receptor – doxorubicin conju-
gate. However, this immunoconjugate did not inhibit the growth of
HepG2 cells.
Many authors suggest that transferrin, which is used in the con-
jugate as a drug carrier, binds to the TRF receptor and enters theytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin
/10.1016/j.tiv.2013.09.013
Fig. 6. Drug uptake (N) and efflux (x) by lymphocytes and leukemic cell lines. (j): Amount of drug in external medium; (e): amount of cell-associated drug. Data are the
means ± SD of six independent experiments.
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The comparison of transport parameters for PBMC, CCRF-CEM, K562 and K562/DOX cells treated with DOX or DOX–TRF. kin—influx rate constant; Vin—influx rate; Ut=60—drug
taken up by cells within 60 min; kout—efflux rate constant; Vout—efflux rate, Et=60—drug removed by cells within 60 min. Results represent means ± SD of six independent
experiments. Statistical analysis was performed by using Tukey’s test and the significance level was assumed as a 6 0.05. We compared the differences for DOX transport and
DOX–TRF within the same cell line (bold text), the differences between normal and leukemic cells in the transport of DOX () or DOX–TRF(#), respectively. Moreover, we also
analyzed the differences in the transport of DOX (single underline) and DOX–TRF conjugate (double underline) between K562 cells sensitive and resistant toQ4 DOX.
Parameters Peripheral blood mononuclear
cells
CCRF-CEM K562 K562/DOX
DOX DOX–TRF DOX DOX–TRF DOX DOX–TRF DOX DOX-TRF
Cells
kin (min1) 0.028 ± 0.005 0.019 ± 0.001 0.012 ± 0.001 0.008 ± 0.002# 0.025 ± 0.002 0.019 ± 0.001 0.008 ± 0.00041 0.021 ± 0.0014
Vin (nmol/
min)




10.179 ± 0.244 3.409 ± 0.347 5.276 ± 0.0335 4.584 ± 0.378 6.917 ± 0.531 3.504 ± 0.687 2.260 ± 0.130 2.720 ± 0.045
kout (min1) 0.0006 ± 0.001 0.0015 ± 0.0002 0.0025 ± 0.001 0.0010 ± 0.0003 0.0040 ± 0.0007 0.0014 ± 0.0005 0.0060 ± 0.0004 0.0007 ± 0.0001
Vout (nmol/
min)






2.535 ± 0.410 1.535 ± 0.358 3.355 ± 0.157 1.378 ± 0.293 3.680 ± 0.406 1.160 ± 0.0643 6.130 ± 0.400 1.010 ± 0.089
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25 September 2013cell through clathrin-mediated endocytosis. DOX–TRF conjugate,
internalized into the cell, is sorted along the trafficking pathway
into endosomes (Mayle et al., 2012). It is proposed that prior to
doxorubicin being separated from the protein, it can be metabo-
lized as free drug (Florent and Monneret, 2008). However, as
shown by Lubgan et al. (2009), glutaraldehyde used in the
conjugate as a linker between the anthracycline and TRF forms a
Shiff base which makes the conjugate very stable in the cytosol.
Therefore, DOX–TRF is not a substrate for endogenous human en-
zymes and may transform in the endosomes/lysosomes to some
derivative metabolites (Kratz et al., 2008). Probably this is the rea-
son why doxorubicin binding to TRF is observed far later in the nu-
cleus than free drug and can cause cell death effectively. This
hypothesis was confirm in the fluorescence microscopy evaluation
which compares the cellular distribution of both drug formulations
(Fig. 4). We have shown that the DOX conjugate was initially often
located in the cytoplasm, possibly in endosomal – like related
structures. The microscopic observation of normal lymphocytes
during drug treatment also showed a different location of DOX
and DOX–TRF, indicating that the mechanism of plasma membrane
passage and subsequent intracellular routing are different between
both drugs. A predominantly cytoplasmic location of DOX–TRF
potentially exposes the conjugate to bioreductive processes that
are known to play an important role in DOX cytotoxicity. The
metabolism of free DOX takes place in the cytosol. DOX, during
redox-activation to a semiquinone intermediate. can generate
superoxide anion that later produces another ROS generation.
ROS which is formed during these transformation can damage
proteins, lipids as well as DNA. Subsequently, oxidative stress is
involved in the initiation or the execution of DNA lesions and
influences the formation of the oxidized DNA bases (Gewirtz,
1999; Injac and Strukelj, 2008).
Our results are in agreement with those of Kovár et al. (2007),
which show differences in the morphology of EL-4T lymphoma
cells exposed to free DOX or DOX conjugated to a HPMA copolymer
carrier via enzymatically (PK1) degradable bonds. The fluorescence
of free DOX was located mainly inside the nucleus and endosomal-
like related structures, whereas the fluorescence of DOX in the PK1
conjugate was mainly found inside the nucleus and acidic organ-
elles. In addition, a doxorubicin–HPMA conjugate bound via a pH
sensitive bond (HYD) presented similar biological properties to
our DOX–TRF conjugate. Controlled release of DOX from HPMA
within cancer cells is likely to be achieved by hydrolysis of hydra-Please cite this article in press as: Szwed, M., et al. Transferrin as a drug carrier: C
conjugate in the human leukemia cells. Toxicol. in Vitro (2013), http://dx.doi.orgzone conjugates (Seib et al., 2006) affecting mainly the cytoplasmic
location of DOX–TRF conjugate.
Differences in intracellular drug accumulation and distribution
of anticancer drugs in cancer cells may contribute to resistance to
chemotherapy. We observed significant differences in the intracel-
lular fate of the two DOX formulations. In our experiments, flow
cytometry was used to evaluate intracellular anthracycline
content. For short incubations, higher fluorescence intensity was
observed for DOX than for DOX–TRF; that was the reverse after
12 h of incubation. Of utmost interest is the difference between
cancer and normal cells. Peripheral blood mononuclear cells were
less sensitive than leukemia cells to DOX–TRF, although both drugs
were removed similarly by cells over 60 min. Ren and Wei (2004)
examined the intracellular levels of an oligodeoxynucleotide–doxo-
rubicin conjugate in human epidermoid carcinoma and suggested
that there are two separate phases in conjugate uptake: a rapid
initial uptake during the first 8 h of incubation followed by a small
increase of drug fluorescence until the end of incubation.
Sensitivity of cancer cells to anticancer agents is enabled by the
presence of constant intra- and extracellular drug concentrations.
An important factor is therefore the clearance of the drug (Chen
et al., 2006). Differences in cytotoxicity between free DOX and
DOX–TRFmay reflect, at least in part, differences in the mechanism
of intracellular uptake of drugs and time-dependent distribution.
We examined the relative contribution of uptake and efflux of
DOX–TRF in the different cell types in order to determine transport
kinetic parameters. DOX uptake was faster than that of DOX–TRF.
The comparison of the kinetic parameters revealed that the
quantity of free DOX taken up by cells within 60 min of incubation
was greater for normal than for cancer cells, whereas no difference
in intracellular DOX–TRF distribution was observed in cancer and
normal cells. Furthermore, the influx and efflux rate constants, as
well as initial influx and efflux rates showed that the kinetics of
drug transport was different for DOX and DOX–TRF. This is in
agreement with the study of Wu et al. (2007) who showed that free
DOX and DOX bound to a macromolecular carrier have very
different kinetic properties, both in terms of in vitro cellular uptake
and in vivo plasma residence time. To improve drug tumor accu-
mulation, liposomes co-encapsulating doxorubicin and verapamil
were conjugated to transferrin to provide a mechanism for tumor
cell – selective targeting (Wu et al., 2007). Encapsulating the drug
in liposomes allows the delivery of the drug into the cells interior
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25 September 2013diffusion of the drug across the membrane. These authors observed
that DOX cellular uptake of TRF–DOX/VER was actually lower than
that of DOX–VER over 72 h. This suggests that the mechanism of
cellular entry (receptor mediated endocytosis for TRF liposomes
versus passive diffusion for free drug) is an important determinant
for cytotoxicity. Similarly, a higher amount of doxorubicin uptake
was also observed in CCRF-CEM cells incubated with a DOX
conjugate obtained by covalent linkage to the DNA aptamer sgc8c
(Huang et al., 2007). It was found that other nanoparticles,
aptamers used as drug carriers led to improved DOX transport to
cancer cells (Chang et al., 2011; Donovan et al., 2011).
In summary, the data presented in the paper suggest that the
cellular mechanism of anti-proliferative action of DOX–TRF is dif-
ferent than that of free DOX. Leukemic cells and normal ones have
different trafficking pathways and levels of enzymes able to cleave
DOX from its carrier. Besides this, the cellular accumulation of the
conjugate is dependent on a dynamic balance between influx and
efflux processes. In addition, active transport mechanisms can
mediate intracellular drug sequestration, rendering possible the
intracellular unbinding of the drug from its carrier.
Binding low molecular weight anticancer therapeutics to
macromolecular carriers may give several advantages, such as im-
proved solubility, biodistribution and pharmacokinetic profiles.
Transferrin conjugates may improve doxorubicin use in many
different ways. We have shown that different mechanisms of
transport are operative for free doxorubicin and DOX–TRF malig-
nant cells were able to retain the conjugate for longer periods of
time than normal lymphocytes. We observed limited effects of
the conjugate on normal cells, which did not over-express the
transferrin receptor. Differences in cytotoxicity and accumulation
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